{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:23:57Z","timestamp":1790537037610,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2408-9","type":"journal-article","created":{"date-parts":[[2016,7,4]],"date-time":"2016-07-04T08:47:22Z","timestamp":1467622042000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Use and misuse of common terminology criteria for adverse events in cancer clinical trials"],"prefix":"10.1186","volume":"16","author":[{"given":"Sheng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Tannock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,4]]},"reference":[{"issue":"13","key":"2408_CR1","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/jnci\/djs259","volume":"104","author":"J Peron","year":"2012","unstructured":"Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst. 2012;104(13):982\u20139.","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"2408_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.2004.10.911","volume":"22","author":"A Trotti","year":"2004","unstructured":"Trotti A, Bentzen SM. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol. 2004;22(1):19\u201322.","journal-title":"J Clin Oncol"},{"issue":"19","key":"2408_CR3","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.2014.55.1903","volume":"32","author":"NM Kuderer","year":"2014","unstructured":"Kuderer NM, Wolff AC. Enhancing therapeutic decision making when options abound: toxicities matter. J Clin Oncol. 2014;32(19):1990\u20133.","journal-title":"J Clin Oncol"},{"issue":"7","key":"2408_CR4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S1470-2045(07)70144-4","volume":"8","author":"A Trotti","year":"2007","unstructured":"Trotti A, Pajak TF, Gwede CK, Paulus R, Cooper J, Forastiere A, Ridge JA, Watkins-Bruner D, Garden AS, Ang KK. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007;8(7):613\u201324.","journal-title":"Lancet Oncol"},{"issue":"35","key":"2408_CR5","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","volume":"30","author":"S Seng","year":"2012","unstructured":"Seng S, Liu Z, Chiu SK, Proverbs-Singh T, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J Clin Oncol. 2012;30(35):4416\u201326.","journal-title":"J Clin Oncol"},{"issue":"23","key":"2408_CR6","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/jnci\/djs435","volume":"104","author":"T Proverbs-Singh","year":"2012","unstructured":"Proverbs-Singh T, Chiu SK, Liu Z, Seng S, Sonpavde G, Choueiri TK, Tsao CK, Yu M, Hahn NM, Oh WK. Arterial thromboembolism in cancer patients treated with cisplatin: a systematic review and meta-analysis. J Natl Cancer Inst. 2012;104(23):1837\u201340.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2408_CR7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/jama.2011.51","volume":"305","author":"V Ranpura","year":"2011","unstructured":"Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA. 2011;305(5):487\u201394.","journal-title":"JAMA"},{"issue":"32","key":"2408_CR8","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","volume":"25","author":"A Trotti","year":"2007","unstructured":"Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. J Clin Oncol. 2007;25(32):5121\u20137.","journal-title":"J Clin Oncol"},{"issue":"4","key":"2408_CR9","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djm324","volume":"100","author":"M Edgerly","year":"2008","unstructured":"Edgerly M, Fojo T. Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst. 2008;100(4):240\u20132.","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"2408_CR10","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","volume":"13","author":"A Trotti","year":"2003","unstructured":"Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176\u201381.","journal-title":"Semin Radiat Oncol"},{"issue":"24","key":"2408_CR11","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1200\/JCO.2011.40.3824","volume":"30","author":"S Niraula","year":"2012","unstructured":"Niraula S, Seruga B, Ocana A, Shao T, Goldstein R, Tannock IF, Amir E. The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol. 2012;30(24):3012\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2408_CR12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1470-2045(13)70511-4","volume":"15","author":"K Kubota","year":"2014","unstructured":"Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, Yokoyama A, Imamura F, Takeda K, Negoro S. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014;15(1):106\u201313.","journal-title":"Lancet Oncol"},{"issue":"2","key":"2408_CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1200\/JCO.2013.52.2219","volume":"32","author":"S Sivendran","year":"2014","unstructured":"Sivendran S, Latif A, McBride RB, Stensland KD, Wisnivesky J, Haines L, Oh WK, Galsky MD. Adverse event reporting in cancer clinical trial publications. J Clin Oncol. 2014;32(2):83\u20139.","journal-title":"J Clin Oncol"},{"issue":"34","key":"2408_CR14","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1200\/JCO.2012.42.5967","volume":"30","author":"E Basch","year":"2012","unstructured":"Basch E, Abernethy AP, Mullins CD, Reeve BB, Smith ML, Coons SJ, Sloan J, Wenzel K, Chauhan C, Eppard W. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012;30(34):4249\u201355.","journal-title":"J Clin Oncol"},{"issue":"24","key":"2408_CR15","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1200\/JCO.2005.05.3959","volume":"24","author":"O Scharf","year":"2006","unstructured":"Scharf O, Colevas AD. Adverse event reporting in publications compared with sponsor database for cancer clinical trials. J Clin Oncol. 2006;24(24):3933\u20138.","journal-title":"J Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2408-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:46:18Z","timestamp":1498311978000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2408-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,4]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2408"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2408-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,4]]},"article-number":"392"}}